183814-30-4

Basic information

• Product Name: (R*,R*)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide fumarate dihydrate
• Synonyms: (r*,r*)-n-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide fumarate dihydrate;Formoterol fumarate dihydrate;Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, rel-, (2E)-2-butenedioate (2:1) (salt), dihydrate;Unii-W34shf8J2k;(±)-(R,R)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamidehemifumarate;Formoterol fumarate dihydrate ,98.5%;Formoterol Fumarate (100 mg);forMaMide fuMarate dihydrate
• CAS NO: 183814-30-4
• Molecular Formula: 2(C19H24N2O4).C4H4O4.2(H2O)
• Molecular Weight: 496.51
• Product Categories: Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;API;Other APIs
• Mol File: 183814-30-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 116-120°C
• Boiling Point: 603.2oC at 760 mmHg
• Flash Point: 318.6oC
• Appearance: white to off-white/
• Vapor Pressure: 2.12E-15mmHg at 25°C
• Storage Temp.: Store at RT
• Solubility: DMSO: soluble20mg/mL
• CAS DataBase Reference: (R*,R*)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide fumarate dihydrate(CAS DataBase Reference)
• NIST Chemistry Reference: (R*,R*)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide fumarate dihydrate(183814-30-4)
• EPA Substance Registry System: (R*,R*)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide fumarate dihydrate(183814-30-4)

Safety Data

• RIDADR: UN 2811 6.1 / PGII
• WGK Germany: 3
• Hazardous Substances Data: 183814-30-4(Hazardous Substances Data)

Usage

Chemical Properties

Pale Yellow Solid

Uses

Different sources of media describe the Uses of 183814-30-4 differently. You can refer to the following data:
1. ForMoterol FuMarate Dihydrate is a selective β2-adrenergic receptor agonist,it is used as an antiasthmatic.
2. A selective β2-adrenergic receptor agonist. Used as an antiasthmatic.

Biological Activity

Potent, selective and long-acting β 2 -adrenoceptor agonist. Displays 330-fold selectivity for β 2 over β 1 receptors (pK d values are 8.12 and 5.58 respectively). Potently relaxes guinea pig trachea (pD 2 = 9.29), and is longer-acting and 100-fold more potent than salbutamol.

Biochem/physiol Actions

β2-Adrenoreceptor agonist.

InChI:InChI=1/C19H24N2O4.C4H4O4.2H2O/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;2-1+;;/t13-,19+;;;/m1.../s1

Upstream product

• 87833-61-2 formoterol hemifumarate 
• 128954-45-0 formoterol 
• 110-17-8 (2E)-but-2-enedioic acid 

Relevant articles and documents

Preparation method and application of formoterol and medicinal salt thereof

The invention provides a preparation method and application of formoterol and medicinal salt thereof, and relates to the technical field of chemical synthesis. The preparation method of formoterol comprises the following steps: reacting a compound shown as a formula I under the action of a palladium-containing catalyst, a hydrogen donor and an alkali reagent to obtain a compound shown as a formulaII, wherein the hydrogen donor is a combination of formic acid and ammonium formate. The compound shown in the formula I contains O-benzyl, N-benzyl, formyl and methoxyl at the same time, hydrogen can be slowly and continuously generated under the action of a palladium-containing catalyst by adopting the combination of a hydrogen donor and an alkali reagent, a method for directly introducing hydrogen in the conventional technology is replaced, benzyl of O-benzyl and N-benzyl on the compound shown in the formula I can be removed, formyl and methoxyl are not affected, the yield and purity of the product are guaranteed, reaction conditions are mild, technological operation is safe and easy to control, and the method is simple, convenient and easy to implement and suitable for large-scale production.

Novel aerosol formulation containing a polar fluorinated molecule

The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar flurorinated molecule and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture thereof.